John Libbey Eurotext



Chronic myeloid leukemia : critical study of therapeutic trials using interferon and analysis of prognostic factors Volume 5, issue 3, Mai - Juin 1999


See all figures


Interferon-alpha (IFN-alpha) has become the standard treatment of chronic myeloid leukemia patients who cannot undergo allogeneic stem cell transplantation. His results are heterogeneous and better for patients with low risk factors or those receiving, the standard dose of IFN-alpha used (5 millions units/m2 per day) ; the results of unicentric studies look superior to those of multicentric studies. The survival of patients is mainly related to the degree of cytogenetic response which is itself predicted by the hematological response after three months of IFN-alpha alone. Many questions remained unanswered such as the optimal dose of IFN-alpha to be used, the indications for interrupting IFN-alpha or the usefullness to combine IFN-alpha with cytosine arabinoside or autologous stem cell transplantation.